Compare CVS Health Corp (CVS) vs Wynn Resorts, Limited (WYNN) Price & Performance

CVS Health trades at $95.67, down slightly by 0.03% today. The stock shows strong fundamental momentum with recent quarterly earnings beats, including Q2 2026 EPS of $2.58 versus $1.87 expected, and raised 2026 guidance. Valuation metrics appear reasonable with a P/E of 24.67 and P/S of 0.29. Technical indicators are mixed with a bullish overall signal but bearish moving averages, with key support at $95 and resistance at $96.

The outlook for CVS is positive, supported by earnings strength and analyst consensus, but risks include margin pressure and rising debt levels. The consensus price target of $115.90 implies significant upside, though investors should monitor execution on guidance and healthcare regulatory changes.

Wynn Resorts (WYNN) trades at $102.50, showing minimal daily movement with a slight 0.04% decline. The stock maintains a bullish technical outlook with strong institutional support, though faces fundamental challenges including declining net margins from 11.17% in 2023 to 4.58% in 2025. Recent Q2 2026 earnings beat expectations with $1.24 EPS versus $0.992 estimates, driven by Macau performance, while Las Vegas operations show weakness. The company faces significant capital expenditure pressures from UAE and Macau expansion projects.

Wynn presents a mixed investment case with 64% analyst buy ratings and $133 consensus target suggesting 30% upside, but faces execution risks from $1.6B+ annual capex and high debt load. The stock's valuation at 25x P/E appears reasonable given recovery potential, though margin compression and project timing create near-term uncertainty. Key catalysts include Macau recovery sustainability and successful UAE project execution by 2027.